Enveric Shows EB-003 Brain Activity in Mice
Enveric Biosciences reports qEEG study results for its lead compound EB-003 in mice, with no abnormal epileptiform discharges recorded.
Updated on Nov. 4, 2026 in Biotech
Enveric Biosciences released qEEG study results for its lead neuroplastogenic compound EB-003 in mice. The study verified central nervous system penetration and showed EB-003 altered cortical electrical oscillations without generating abnormal epileptiform discharges.
Why it matters
The preclinical data offers an early look at how EB-003 affects brain activity compared with DMT, which produced epileptic-like spikes and severe muscular spasms in the same testing. Enveric plans to use qEEG monitoring to guide future human studies.
The evidence comes from preclinical continuous qEEG recordings in mice spanning diverse brain-wave frequency ranges, with zero abnormal epileptiform discharges recorded for EB-003 versus epileptic-like spikes and severe muscular spasms produced by DMT in the same testing. Whether these mouse results predict human neurological responses remains unknown.
The players
Enveric Biosciences
Enveric Biosciences is a biotechnology company developing neuroplastogenic small-molecule therapeutics, including its lead compound EB-003.
The details
Enveric Biosciences, a biotechnology firm developing neuroplastogenic small-molecule therapeutics, used continuous qEEG recordings to measure EB-003's effects on electrical oscillations in cortical regions. EB-003 is engineered to target 5-HT2A and 5-HT1B receptors and modulated brain activity across prefrontal and parietal cortex areas.
Timeline
November 4, 2026: Enveric released the qEEG study results for EB-003.
The Tech Race
Enveric's EB-003 is being evaluated against DMT, a classic psychedelic, to see whether a neuroplastogenic compound can produce brain-activity effects without DMT's seizure-like and muscle-spasm side effects. The comparison reflects a broader push in biotech to design psychedelic-inspired therapies that avoid the risks of legacy compounds.
For patients and the public, this is early preclinical work and does not yet change treatment options or access. The main near-term relevance is for investors and researchers tracking whether EB-003 can advance into human trials.
The takeaway
Preclinical brain-activity data from mice is an early signal, not evidence of human safety or effectiveness. Readers should watch for first-in-human results before drawing conclusions about EB-003.
What happens next
Enveric plans to use qEEG monitoring as a pharmacodynamic biomarker during planned first-in-human studies, though no specific dates were provided.
Further reading
Explore more Biotech developments in the United States.
